Selected research
Market Outlook & Growth Opportunities
Global Rare Disease Pharmaceutical Service Market Outlook and Growth Opportunities 2026
Market perspective
The global Rare Disease Pharmaceutical Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Rare Disease Pharmaceutical Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Rare Disease Pharmaceutical Service market include Ultragenyx, Chiesi, Sciensus, Abbvie, Orpharma, Amgen, Recordati, Novartis and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Rare Disease Pharmaceutical Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rare Disease Pharmaceutical Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rare Disease Pharmaceutical Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rare Disease Pharmaceutical Service market.
Rare Disease Pharmaceutical Service Segment by Company
Ultragenyx
Chiesi
Sciensus
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Shire
Merck
Pfizer
Biogen
Sanofi
AstraZeneca
Takeda
Rare Disease Pharmaceutical Service Segment by Type
Drug Discovery
Clinical Trials
Others
Rare Disease Pharmaceutical Service Segment by Application
Congenital and Genetic Diseases
Tumors and Cancer
Endocrine Diseases
Others
Rare Disease Pharmaceutical Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Rare Disease Pharmaceutical Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Rare Disease Pharmaceutical Service key companies, revenue, market share, and recent developments.
3. To split the Rare Disease Pharmaceutical Service breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Rare Disease Pharmaceutical Service market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Rare Disease Pharmaceutical Service significant trends, drivers, influence factors in global and regions.
6. To analyze Rare Disease Pharmaceutical Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Pharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Pharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Pharmaceutical Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rare Disease Pharmaceutical Service industry.
Chapter 3: Detailed analysis of Rare Disease Pharmaceutical Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Rare Disease Pharmaceutical Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Rare Disease Pharmaceutical Service in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Rare Disease Pharmaceutical Service Industry Trends
Table 2. Rare Disease Pharmaceutical Service Industry Drivers
Table 3. Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
Table 4. Rare Disease Pharmaceutical Service Industry Restraints
Table 5. Global Rare Disease Pharmaceutical Service Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Rare Disease Pharmaceutical Service Revenue Share by Company (2021-2026)
Table 7. Global Rare Disease Pharmaceutical Service Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Rare Disease Pharmaceutical Service Key Company Manufacturing Base & Headquarters
Table 9. Global Rare Disease Pharmaceutical Service Company, Product Type & Application
Table 10. Global Rare Disease Pharmaceutical Service Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Rare Disease Pharmaceutical Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Drug Discovery
Table 15. Significant Companies of Clinical Trials
Table 16. Significant Companies of Others
Table 17. Global Rare Disease Pharmaceutical Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Rare Disease Pharmaceutical Service Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Rare Disease Pharmaceutical Service Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Rare Disease Pharmaceutical Service Sales Value Share by Type (2021-2026)
Table 21. Global Rare Disease Pharmaceutical Service Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of Congenital and Genetic Diseases
Table 23. Significant Companies of Tumors and Cancer
Table 24. Significant Companies of Endocrine Diseases
Table 25. Significant Companies of Others
Table 26. Global Rare Disease Pharmaceutical Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Rare Disease Pharmaceutical Service Sales Value by Application (2021-2026) & (US$ Million)
Table 28. Global Rare Disease Pharmaceutical Service Sales Value by Application (2027-2032) & (US$ Million)
Table 29. Global Rare Disease Pharmaceutical Service Sales Value Share by Application (2021-2026)
Table 30. Global Rare Disease Pharmaceutical Service Sales Value Share by Application (2027-2032)
Table 31. Global Rare Disease Pharmaceutical Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Rare Disease Pharmaceutical Service Sales Value by Region (2021-2026) & (US$ Million)
Table 33. Global Rare Disease Pharmaceutical Service Sales Value Share by Region (2021-2026)
Table 34. Global Rare Disease Pharmaceutical Service Sales Value by Region (2027-2032) & (US$ Million)
Table 35. Global Rare Disease Pharmaceutical Service Sales Value Share by Region (2027-2032)
Table 36. Global Rare Disease Pharmaceutical Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Rare Disease Pharmaceutical Service Sales Value by Country (2021-2026) & (US$ Million)
Table 38. Global Rare Disease Pharmaceutical Service Sales Value Market Share by Country (2021-2026)
Table 39. Global Rare Disease Pharmaceutical Service Sales Value by Country (2027-2032) & (US$ Million)
Table 40. Global Rare Disease Pharmaceutical Service Sales Value Market Share by Country (2027-2032)
Table 41. Ultragenyx Company Information
Table 42. Ultragenyx Business Overview
Table 43. Ultragenyx Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
Table 45. Ultragenyx Recent Development
Table 46. Chiesi Company Information
Table 47. Chiesi Business Overview
Table 48. Chiesi Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Chiesi Rare Disease Pharmaceutical Service Product Portfolio
Table 50. Chiesi Recent Development
Table 51. Sciensus Company Information
Table 52. Sciensus Business Overview
Table 53. Sciensus Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Sciensus Rare Disease Pharmaceutical Service Product Portfolio
Table 55. Sciensus Recent Development
Table 56. Abbvie Company Information
Table 57. Abbvie Business Overview
Table 58. Abbvie Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Abbvie Rare Disease Pharmaceutical Service Product Portfolio
Table 60. Abbvie Recent Development
Table 61. Orpharma Company Information
Table 62. Orpharma Business Overview
Table 63. Orpharma Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. Orpharma Rare Disease Pharmaceutical Service Product Portfolio
Table 65. Orpharma Recent Development
Table 66. Amgen Company Information
Table 67. Amgen Business Overview
Table 68. Amgen Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Amgen Rare Disease Pharmaceutical Service Product Portfolio
Table 70. Amgen Recent Development
Table 71. Recordati Company Information
Table 72. Recordati Business Overview
Table 73. Recordati Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Recordati Rare Disease Pharmaceutical Service Product Portfolio
Table 75. Recordati Recent Development
Table 76. Novartis Company Information
Table 77. Novartis Business Overview
Table 78. Novartis Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Novartis Rare Disease Pharmaceutical Service Product Portfolio
Table 80. Novartis Recent Development
Table 81. Celgene Company Information
Table 82. Celgene Business Overview
Table 83. Celgene Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. Celgene Rare Disease Pharmaceutical Service Product Portfolio
Table 85. Celgene Recent Development
Table 86. Amryt Pharma Company Information
Table 87. Amryt Pharma Business Overview
Table 88. Amryt Pharma Rare Disease Pharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
Table 90. Amryt Pharma Recent Development
Table 91. Johnson & Johnson Company Information
Table 92. Johnson & Johnson Business Overview
Table 93. Johnson & Johnson Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 94. Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
Table 95. Johnson & Johnson Recent Development
Table 96. GSK Company Information
Table 97. GSK Business Overview
Table 98. GSK Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 99. GSK Rare Disease Pharmaceutical Service Product Portfolio
Table 100. GSK Recent Development
Table 101. Shire Company Information
Table 102. Shire Business Overview
Table 103. Shire Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 104. Shire Rare Disease Pharmaceutical Service Product Portfolio
Table 105. Shire Recent Development
Table 106. Merck Company Information
Table 107. Merck Business Overview
Table 108. Merck Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 109. Merck Rare Disease Pharmaceutical Service Product Portfolio
Table 110. Merck Recent Development
Table 111. Pfizer Company Information
Table 112. Pfizer Business Overview
Table 113. Pfizer Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 114. Pfizer Rare Disease Pharmaceutical Service Product Portfolio
Table 115. Pfizer Recent Development
Table 116. Biogen Company Information
Table 117. Biogen Business Overview
Table 118. Biogen Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 119. Biogen Rare Disease Pharmaceutical Service Product Portfolio
Table 120. Biogen Recent Development
Table 121. Sanofi Company Information
Table 122. Sanofi Business Overview
Table 123. Sanofi Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 124. Sanofi Rare Disease Pharmaceutical Service Product Portfolio
Table 125. Sanofi Recent Development
Table 126. AstraZeneca Company Information
Table 127. AstraZeneca Business Overview
Table 128. AstraZeneca Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 129. AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
Table 130. AstraZeneca Recent Development
Table 131. Takeda Company Information
Table 132. Takeda Business Overview
Table 133. Takeda Rare Disease Pharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 134. Takeda Rare Disease Pharmaceutical Service Product Portfolio
Table 135. Takeda Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Authors List of This Report
Table 138. Secondary Sources
Table 139. Primary Sources
List of Figures
Figure 1. Rare Disease Pharmaceutical Service Product Image
Figure 2. Global Rare Disease Pharmaceutical Service Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 4. Global Rare Disease Pharmaceutical Service Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Drug Discovery Image
Figure 8. Clinical Trials Image
Figure 9. Others Image
Figure 10. Global Rare Disease Pharmaceutical Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Rare Disease Pharmaceutical Service Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Rare Disease Pharmaceutical Service Sales Value Share by Type (2021-2032)
Figure 13. Congenital and Genetic Diseases Image
Figure 14. Tumors and Cancer Image
Figure 15. Endocrine Diseases Image
Figure 16. Others Image
Figure 17. Global Rare Disease Pharmaceutical Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 18. Global Rare Disease Pharmaceutical Service Sales Value Share 2021 VS 2025 VS 2032
Figure 19. Global Rare Disease Pharmaceutical Service Sales Value Share by Application (2021-2032)
Figure 20. Global Rare Disease Pharmaceutical Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 21. Global Rare Disease Pharmaceutical Service Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 22. North America Rare Disease Pharmaceutical Service Sales Value (2021-2032) & (US$ Million)
Figure 23. North America Rare Disease Pharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Europe Rare Disease Pharmaceutical Service Sales Value (2021-2032) & (US$ Million)
Figure 25. Europe Rare Disease Pharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Asia-Pacific Rare Disease Pharmaceutical Service Sales Value (2021-2032) & (US$ Million)
Figure 27. Asia-Pacific Rare Disease Pharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032
Figure 28. South America Rare Disease Pharmaceutical Service Sales Value (2021-2032) & (US$ Million)
Figure 29. South America Rare Disease Pharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Middle East & Africa Rare Disease Pharmaceutical Service Sales Value (2021-2032) & (US$ Million)
Figure 31. Middle East & Africa Rare Disease Pharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032
Figure 32. USA Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. USA Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. USA Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Canada Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Canada Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Canada Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Mexico Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Mexico Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Mexico Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. Germany Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. Germany Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. Germany Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. France Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. France Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. France Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. U.K. Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. U.K. Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. U.K. Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Italy Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Italy Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Italy Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Spain Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Spain Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Spain Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Russia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Russia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Russia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Netherlands Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Netherlands Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Netherlands Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Nordic Countries Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Nordic Countries Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. China Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. China Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. China Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Japan Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Japan Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Japan Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. South Korea Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. South Korea Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. South Korea Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. India Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. India Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. India Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Australia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Australia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Australia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Southeast Asia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Southeast Asia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Brazil Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Brazil Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Brazil Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Argentina Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Argentina Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Argentina Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Chile Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Chile Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Chile Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Colombia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Colombia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Colombia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Peru Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Peru Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Peru Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Israel Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Israel Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Israel Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. UAE Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. UAE Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. UAE Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Turkey Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Turkey Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Turkey Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Iran Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Iran Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Iran Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Egypt Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Egypt Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Egypt Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Years Considered
Figure 117. Research Process
Figure 118. Key Executives Interviewed
Scope & coverage.
Types
- Drug Discovery
- Clinical Trials
- Others
Applications
- Congenital and Genetic Diseases
- Tumors and Cancer
- Endocrine Diseases
- Others
Companies covered
- Ultragenyx
- Chiesi
- Sciensus
- Abbvie
- Orpharma
- Amgen
- Recordati
- Novartis
- Celgene
- Amryt Pharma
- Johnson & Johnson
- GSK
- Shire
- Merck
- Pfizer
- Biogen
- Sanofi
- AstraZeneca
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rare Disease Pharmaceutical Service Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Rare Disease Pharmaceutical Service Market Dynamics
- 2.1 Rare Disease Pharmaceutical Service Industry Trends
- 2.2 Rare Disease Pharmaceutical Service Industry Drivers
- 2.3 Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
- 2.4 Rare Disease Pharmaceutical Service Industry Restraints
3 Rare Disease Pharmaceutical Service Market by Company
- 3.1 Global Rare Disease Pharmaceutical Service Company Revenue Ranking in 2025
- 3.2 Global Rare Disease Pharmaceutical Service Revenue by Company (2021-2026)
- 3.3 Global Rare Disease Pharmaceutical Service Company Ranking (2024-2026)
- 3.4 Global Rare Disease Pharmaceutical Service Company Manufacturing Base and Headquarters
- 3.5 Global Rare Disease Pharmaceutical Service Company Product Type and Application
- 3.6 Global Rare Disease Pharmaceutical Service Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Rare Disease Pharmaceutical Service Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Rare Disease Pharmaceutical Service Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Rare Disease Pharmaceutical Service Market by Type
- 4.1 Rare Disease Pharmaceutical Service Type Introduction
- 4.1.1 Drug Discovery
- 4.1.2 Clinical Trials
- 4.1.3 Others
- 4.2 Global Rare Disease Pharmaceutical Service Sales Value by Type
- 4.2.1 Global Rare Disease Pharmaceutical Service Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rare Disease Pharmaceutical Service Sales Value by Type (2021-2032)
- 4.2.3 Global Rare Disease Pharmaceutical Service Sales Value Share by Type (2021-2032)
5 Rare Disease Pharmaceutical Service Market by Application
- 5.1 Rare Disease Pharmaceutical Service Application Introduction
- 5.1.1 Congenital and Genetic Diseases
- 5.1.2 Tumors and Cancer
- 5.1.3 Endocrine Diseases
- 5.1.4 Others
- 5.2 Global Rare Disease Pharmaceutical Service Sales Value by Application
- 5.2.1 Global Rare Disease Pharmaceutical Service Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rare Disease Pharmaceutical Service Sales Value by Application (2021-2032)
- 5.2.3 Global Rare Disease Pharmaceutical Service Sales Value Share by Application (2021-2032)
6 Rare Disease Pharmaceutical Service Regional Value Analysis
- 6.1 Global Rare Disease Pharmaceutical Service Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rare Disease Pharmaceutical Service Sales Value by Region (2021-2032)
- 6.2.1 Global Rare Disease Pharmaceutical Service Sales Value by Region: 2021-2026
- 6.2.2 Global Rare Disease Pharmaceutical Service Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rare Disease Pharmaceutical Service Sales Value (2021-2032)
- 6.3.2 North America Rare Disease Pharmaceutical Service Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Rare Disease Pharmaceutical Service Sales Value (2021-2032)
- 6.4.2 Europe Rare Disease Pharmaceutical Service Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Rare Disease Pharmaceutical Service Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Rare Disease Pharmaceutical Service Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Rare Disease Pharmaceutical Service Sales Value (2021-2032)
- 6.6.2 South America Rare Disease Pharmaceutical Service Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Rare Disease Pharmaceutical Service Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Rare Disease Pharmaceutical Service Sales Value Share by Country, 2025 VS 2032
7 Rare Disease Pharmaceutical Service Country-level Value Analysis
- 7.1 Global Rare Disease Pharmaceutical Service Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Rare Disease Pharmaceutical Service Sales Value by Country (2021-2032)
- 7.2.1 Global Rare Disease Pharmaceutical Service Sales Value by Country (2021-2026)
- 7.2.2 Global Rare Disease Pharmaceutical Service Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.7.2 France Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.14.2 China Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.17.2 India Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Rare Disease Pharmaceutical Service Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Rare Disease Pharmaceutical Service Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Rare Disease Pharmaceutical Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Ultragenyx
- 8.1.1 Ultragenyx Company Information
- 8.1.2 Ultragenyx Business Overview
- 8.1.3 Ultragenyx Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.1.4 Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
- 8.1.5 Ultragenyx Recent Developments
- 8.2 Chiesi
- 8.2.1 Chiesi Company Information
- 8.2.2 Chiesi Business Overview
- 8.2.3 Chiesi Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.2.4 Chiesi Rare Disease Pharmaceutical Service Product Portfolio
- 8.2.5 Chiesi Recent Developments
- 8.3 Sciensus
- 8.3.1 Sciensus Company Information
- 8.3.2 Sciensus Business Overview
- 8.3.3 Sciensus Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.3.4 Sciensus Rare Disease Pharmaceutical Service Product Portfolio
- 8.3.5 Sciensus Recent Developments
- 8.4 Abbvie
- 8.4.1 Abbvie Company Information
- 8.4.2 Abbvie Business Overview
- 8.4.3 Abbvie Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.4.4 Abbvie Rare Disease Pharmaceutical Service Product Portfolio
- 8.4.5 Abbvie Recent Developments
- 8.5 Orpharma
- 8.5.1 Orpharma Company Information
- 8.5.2 Orpharma Business Overview
- 8.5.3 Orpharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.5.4 Orpharma Rare Disease Pharmaceutical Service Product Portfolio
- 8.5.5 Orpharma Recent Developments
- 8.6 Amgen
- 8.6.1 Amgen Company Information
- 8.6.2 Amgen Business Overview
- 8.6.3 Amgen Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.6.4 Amgen Rare Disease Pharmaceutical Service Product Portfolio
- 8.6.5 Amgen Recent Developments
- 8.7 Recordati
- 8.7.1 Recordati Company Information
- 8.7.2 Recordati Business Overview
- 8.7.3 Recordati Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.7.4 Recordati Rare Disease Pharmaceutical Service Product Portfolio
- 8.7.5 Recordati Recent Developments
- 8.8 Novartis
- 8.8.1 Novartis Company Information
- 8.8.2 Novartis Business Overview
- 8.8.3 Novartis Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.8.4 Novartis Rare Disease Pharmaceutical Service Product Portfolio
- 8.8.5 Novartis Recent Developments
- 8.9 Celgene
- 8.9.1 Celgene Company Information
- 8.9.2 Celgene Business Overview
- 8.9.3 Celgene Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.9.4 Celgene Rare Disease Pharmaceutical Service Product Portfolio
- 8.9.5 Celgene Recent Developments
- 8.10 Amryt Pharma
- 8.10.1 Amryt Pharma Company Information
- 8.10.2 Amryt Pharma Business Overview
- 8.10.3 Amryt Pharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.10.4 Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
- 8.10.5 Amryt Pharma Recent Developments
- 8.11 Johnson & Johnson
- 8.11.1 Johnson & Johnson Company Information
- 8.11.2 Johnson & Johnson Business Overview
- 8.11.3 Johnson & Johnson Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.11.4 Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
- 8.11.5 Johnson & Johnson Recent Developments
- 8.12 GSK
- 8.12.1 GSK Company Information
- 8.12.2 GSK Business Overview
- 8.12.3 GSK Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.12.4 GSK Rare Disease Pharmaceutical Service Product Portfolio
- 8.12.5 GSK Recent Developments
- 8.13 Shire
- 8.13.1 Shire Company Information
- 8.13.2 Shire Business Overview
- 8.13.3 Shire Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.13.4 Shire Rare Disease Pharmaceutical Service Product Portfolio
- 8.13.5 Shire Recent Developments
- 8.14 Merck
- 8.14.1 Merck Company Information
- 8.14.2 Merck Business Overview
- 8.14.3 Merck Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.14.4 Merck Rare Disease Pharmaceutical Service Product Portfolio
- 8.14.5 Merck Recent Developments
- 8.15 Pfizer
- 8.15.1 Pfizer Company Information
- 8.15.2 Pfizer Business Overview
- 8.15.3 Pfizer Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.15.4 Pfizer Rare Disease Pharmaceutical Service Product Portfolio
- 8.15.5 Pfizer Recent Developments
- 8.16 Biogen
- 8.16.1 Biogen Company Information
- 8.16.2 Biogen Business Overview
- 8.16.3 Biogen Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.16.4 Biogen Rare Disease Pharmaceutical Service Product Portfolio
- 8.16.5 Biogen Recent Developments
- 8.17 Sanofi
- 8.17.1 Sanofi Company Information
- 8.17.2 Sanofi Business Overview
- 8.17.3 Sanofi Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.17.4 Sanofi Rare Disease Pharmaceutical Service Product Portfolio
- 8.17.5 Sanofi Recent Developments
- 8.18 AstraZeneca
- 8.18.1 AstraZeneca Company Information
- 8.18.2 AstraZeneca Business Overview
- 8.18.3 AstraZeneca Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.18.4 AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
- 8.18.5 AstraZeneca Recent Developments
- 8.19 Takeda
- 8.19.1 Takeda Company Information
- 8.19.2 Takeda Business Overview
- 8.19.3 Takeda Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
- 8.19.4 Takeda Rare Disease Pharmaceutical Service Product Portfolio
- 8.19.5 Takeda Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst